There are 2789 resources available
739P - Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial
Presenter: Renaud Sabatier
Session: ePoster Display
740P - Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
Presenter: Kristina Lindemann
Session: ePoster Display
741P - Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study
Presenter: Louis Mourani
Session: ePoster Display
742P - Survival in patients (pts) with advanced ovarian cancer (AOC) changes with cumulative number of risk factors (RFs): A US real-world (RW) analysis
Presenter: Dana Chase
Session: ePoster Display
743P - Real-world outcomes in patients treated with trametinib for low grade serous ovarian carcinoma
Presenter: Rohan Shotton
Session: ePoster Display
744P - Use of PARPi among patients with advanced ovarian cancer: Results from a real-world database
Presenter: Shaheenah Dawood
Session: ePoster Display
746P - Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France
Presenter: Manuel Rodrigues
Session: ePoster Display
747P - Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study
Presenter: Mark Lythgoe
Session: ePoster Display
748P - Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Presenter: Margarita Romeo Marin
Session: ePoster Display